Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: A plea for deep remission

Journal of Crohn's and Colitis

Volumn 9, Issue 1, 2015, Pages 50-55

  Mooiweer, Erik ^a   Severs, Mirjam ^a   Schipper, Marguerite E I ^a   Fidder, Herma H ^a   Siersema, Peter D ^a   Laheij, Robert J F ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Calprotectin; IBD; Mucosal healing; Relapse

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CALGRANULIN; MESALAZINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; COLON MUCOSA; COLONOSCOPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FECES ANALYSIS; FECES LEVEL; FEMALE; FOLLOW UP; GEBOES SCORING SYSTEM; HEALING; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; RISK ASSESSMENT; RISK REDUCTION; SAMPLING; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; CHEMISTRY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; INFLAMMATORY BOWEL DISEASES; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; COLONOSCOPY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84929317850     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju003     Document Type: Article

References (29)

1. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201
2. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22
3. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010;138:463-8; quiz e10-1
4. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-5
5. Osada T, Ohkusa T, Okayasu I, et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008;23 Suppl 2:S262-7
6. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-24
7. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14: 40-6
8. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013;19:332-41
9. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6
10. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124:880-8
11. Moum B, Ekbom A, Vatn MH, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999;94:1564-9
12. Peyrin-Biroulet L, Bressenot A, Kampman W. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2013
13. Mao R, Xiao YL, Gao X et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-9
14. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9
15. Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol 2012;107:1684-92
16. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013;15:315
17. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8
18. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis 2010;4:144-52
19. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8
20. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14
21. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22
22. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008;14:669-73
23. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9
24. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37
25. Meling TR, Aabakken L, Roseth A, et al. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996;31:339-44
26. Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:841-5
27. Feagins LA, Melton SD, Iqbal R, et al. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013;19:1477-82
28. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8
29. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20